Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 74 |
| Active Pipeline (Recruiting Now) | 33 (25) |
| Completed vs Stopped Early | 31 / 10 (13.5%) |
| Median Closed Actual Enrollment | 47 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Medical University of South Carolina | Charleston, SC | 52 |
| Emory Winship Cancer Institute | Atlanta, GA | 3 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT02633163 | Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE) | Phase II | COMPLETED |
Explore interactive annual charts and M&A subsidiary rollups in the Medical University of South Carolina Interactive Dossier, benchmark peers in Neurology, Psychiatry, and Pain, or review the Healthcare Price & Patent Cliff Crosswalk.